Journal article
MRI and 18FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial
Abstract
PURPOSE: To explore a prognostic or predictive role of MRI and O-(2-18F-fluoroethyl)-L-tyrosine (18FET) PET parameters for outcome in the randomized multicenter trial ARTE that compared bevacizumab plus radiotherapy with radiotherpay alone in elderly patients with glioblastoma.
PATIENTS AND METHODS: Patients with isocitrate dehydrogenase wild-type glioblastoma ages 65 years or older were included in this post hoc analysis. Tumor volumetric and …
Authors
Wirsching H-G; Roelcke U; Weller J; Hundsberger T; Hottinger AF; von Moos R; Caparrotti F; Conen K; Remonda L; Roth P
Journal
Clinical Cancer Research, Vol. 27, No. 1, pp. 179–188
Publisher
American Association for Cancer Research (AACR)
Publication Date
January 1, 2021
DOI
10.1158/1078-0432.ccr-20-2096
ISSN
1078-0432